851.21
price down icon2.61%   -22.79
pre-market  Pre-market:  853.58   2.37   +0.28%
loading
Lilly Eli Co stock is traded at $851.21, with a volume of 3.88M. It is down -2.61% in the last 24 hours and down -3.08% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$874.00
Open:
$866.04
24h Volume:
3.88M
Relative Volume:
1.24
Market Cap:
$760.43B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
37.68
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-7.63%
1M Performance:
-3.08%
6M Performance:
+4.63%
1Y Performance:
-3.84%
1-Day Range:
Value
$850.51
$869.02
1-Week Range:
Value
$850.51
$930.00
52-Week Range:
Value
$623.78
$1,133.95

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2026-04-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, AZN, MRK

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LLY icon
LLY
Lilly Eli Co
851.21 780.79B 65.18B 20.64B 5.96B 22.59
JNJ icon
JNJ
Johnson Johnson
227.35 548.34B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
203.89 349.67B 61.16B 4.19B 17.82B 2.3614
AZN icon
AZN
Astrazeneca Plc
185.20 289.51B 58.80B 10.24B 8.98B 3.2788
MRK icon
MRK
Merck Co Inc
110.95 271.76B 64.93B 18.26B 12.36B 7.2751

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Downgrade HSBC Securities Hold → Reduce
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
02:47 AM

Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga

02:47 AM
pulisher
12:55 PM

The Stepwise Path Lilly Mapped From Paper To Digital Logbooks - Bioprocess Online

12:55 PM
pulisher
Apr 29, 2026

Eli Lilly’s $20.9 Billion M&A Spree Signals a Strategic Pivot Ahead of a Pivotal Earnings Report - AD HOC NEWS

Apr 29, 2026
pulisher
Apr 29, 2026

Is Eli Lilly (LLY) Offering A Chance After Recent Share Price Pullback? - simplywall.st

Apr 29, 2026
pulisher
Apr 29, 2026

Lilly signs $2.25B deal with California AI firm to develop genetic medicine - Inside INdiana Business

Apr 29, 2026
pulisher
Apr 29, 2026

Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch

Apr 29, 2026
pulisher
Apr 29, 2026

Sun Pharma, Lilly Lead Latest Healthcare Deal Rush - marketscreener.com

Apr 29, 2026
pulisher
Apr 29, 2026

Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings - Investopedia

Apr 29, 2026
pulisher
Apr 29, 2026

Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact - Pharmaceutical Technology

Apr 29, 2026
pulisher
Apr 29, 2026

Lilly signs $2.25B deal with California-based AI firm to develop genetic medicine - dailyjournal.net

Apr 29, 2026
pulisher
Apr 29, 2026

Novo Nordisk A/S Stock (NVO) Moved Down by 3.07% on Apr 29: Drivers Behind the Movement - TradingKey

Apr 29, 2026
pulisher
Apr 29, 2026

Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals - Insider Monkey

Apr 29, 2026
pulisher
Apr 29, 2026

Eli Lilly Stock (LLY) Falls as Canada Approves Generic Weight-Loss Drugs - TipRanks

Apr 29, 2026
pulisher
Apr 29, 2026

What triggered Eli Lilly shares' latest price pullback - Traders Union

Apr 29, 2026
pulisher
Apr 29, 2026

Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started - GlobeNewswire Inc.

Apr 29, 2026
pulisher
Apr 29, 2026

Eli Lilly Stock (LLY) Opinions on Foundayo Pill Launch - Quiver Quantitative

Apr 29, 2026
pulisher
Apr 29, 2026

AI Models Split on How Much Upside Is Left in Eli Lilly (LLY) - TipRanks

Apr 29, 2026
pulisher
Apr 29, 2026

Eli Lilly investors are eager for Foundayo insight after early launch data - Reuters

Apr 29, 2026
pulisher
Apr 29, 2026

Eli Lilly (LLY) Stock; Edges Higher as $2.25B AI Gene-Editing Deal Sparks Biotech Optimism - CoinCentral

Apr 29, 2026
pulisher
Apr 29, 2026

Wegovy’s Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch - Seeking Alpha

Apr 29, 2026
pulisher
Apr 28, 2026

Eli Lilly Expands Into AI DNA Editing With Profluent Enzyme Deal - simplywall.st

Apr 28, 2026
pulisher
Apr 28, 2026

Is Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks So - AOL.com

Apr 28, 2026
pulisher
Apr 28, 2026

Boehringer’s obesity drug shows 16.6% weight loss; more data needed - statnews.com

Apr 28, 2026
pulisher
Apr 28, 2026

FUTURHEALTH LEADS IN PROVIDING ELI LILLY'S ORAL GLP-1, ORFORGLIPRON, BROADENING ACCESS TO ADVANCED NON-INJECTABLE THERAPY - Intellectia AI

Apr 28, 2026
pulisher
Apr 28, 2026

Eli Lilly, Profluent Target Complex Genetic Diseases With AI-Driven Custom DNA Tools - Benzinga

Apr 28, 2026
pulisher
Apr 28, 2026

AI company Profluent strikes potential $2 billion deal with drugmaker Lilly - The Business Journals

Apr 28, 2026
pulisher
Apr 28, 2026

FuturHealth Among the First to Offer Eli Lilly's Oral GLP-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment - PR Newswire

Apr 28, 2026
pulisher
Apr 28, 2026

Teva v. Lilly -- Clarifies Written Description of Method Claims Involving A Genus - JD Supra

Apr 28, 2026
pulisher
Apr 28, 2026

Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion - Reuters

Apr 28, 2026
pulisher
Apr 28, 2026

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ - BioSpace

Apr 28, 2026
pulisher
Apr 28, 2026

Profluent Partners with Eli Lilly (LLY) in $2.25B Drug Developme - GuruFocus

Apr 28, 2026
pulisher
Apr 28, 2026

Lilly adds potential first-in-class Type II JAK2 inhibitor to haematology portfolio - European Pharmaceutical Review

Apr 28, 2026
pulisher
Apr 28, 2026

Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing - Fierce Biotech

Apr 28, 2026
pulisher
Apr 28, 2026

Analysts Are Bullish on Top Healthcare Stocks: UnitedHealth (UNH), Eli Lilly & Co (LLY) - The Globe and Mail

Apr 28, 2026
pulisher
Apr 28, 2026

Lilly, Profluent ink deal on AI drugs worth up to $2.25 billion - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

Eli Lilly inks gene therapy deal worth up to $2.25B with Profluent - Seeking Alpha

Apr 28, 2026
pulisher
Apr 28, 2026

Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion - Bloomberg.com

Apr 28, 2026
pulisher
Apr 28, 2026

Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine - Business Wire

Apr 28, 2026
pulisher
Apr 28, 2026

From weight loss to wakefulness: Has Eli Lilly found the next goldmine? - medwatch.com

Apr 28, 2026
pulisher
Apr 28, 2026

Eli Lilly is acquiring blood cancer drug developer Ajax Therapeutics for up to $2.3 billion - qz.com

Apr 28, 2026
pulisher
Apr 28, 2026

Pharmaceutical Stock Pulling Back Before Earnings - Schaeffer's Investment Research

Apr 28, 2026
pulisher
Apr 28, 2026

Analysts Reiterate Bullish Outlook on Eli Lilly and Company (LLY) Following Kelonia Acquisition - Insider Monkey

Apr 28, 2026
pulisher
Apr 27, 2026

Eli Lilly’s Oncology Push Sparks S&P 500 Futures Buzz - Kalkine Media

Apr 27, 2026
pulisher
Apr 27, 2026

Eli Lilly (LLY) Anticipates Strong Q1 Earnings Growth Driven by Obesity Treatments - GuruFocus

Apr 27, 2026
pulisher
Apr 27, 2026

Eli Lilly Expands Oncology With Ajax Deal As Valuation Gap Persists - Yahoo Finance

Apr 27, 2026
pulisher
Apr 27, 2026

Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus

Apr 27, 2026
pulisher
Apr 27, 2026

Eli Lilly Expands Oncology Portfolio with $2.3B Acquisition - Powder & Bulk Solids

Apr 27, 2026
pulisher
Apr 27, 2026

Bernard Fox: Eli Lilly’s $7B Acquisition of Kelonia is a Leap Toward Democratizing CAR-T - Oncodaily

Apr 27, 2026
pulisher
Apr 27, 2026

Jim Cramer Says Eli Lilly “Will Tell a Good Story When It Reports” - Insider Monkey

Apr 27, 2026
pulisher
Apr 27, 2026

Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy - Law360

Apr 27, 2026
pulisher
Apr 27, 2026

Eli Lilly’s Been On An Acquisition Spree This Year – Here’s A Look At Its Major Deals - Stocktwits

Apr 27, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
JNJ JNJ
$227.35
price down icon 0.19%
$203.89
price up icon 3.14%
AZN AZN
$185.20
price down icon 0.79%
MRK MRK
$110.95
price up icon 0.84%
NVS NVS
$142.94
price down icon 1.76%
Cap:     |  Volume (24h):